

[Emtricitabine + tenofovir](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.2. Antiretrovirals](#) [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

ATC codes: [J05AR03](#)

Indication

Contact with or exposure to human immunodeficiency virus ICD11 code: [OC90.6](#)

INN

Emtricitabine + tenofovir

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid:** 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[lamivudine + tenofovir](#) (ATC codes: [J05AR12](#))

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Read more [about patents](#).

Wikipedia

[Emtricitabine + tenofovir](#)

DrugBank

[Emtricitabine](#),

[Tenofovir \(Tenofovir disoproxil\)](#)

Summary of evidence and Expert Committee recommendations



Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for emtricitabine + tenofovir on the EML.